The Louisville-based pharmaceutical firm earned the distinction for its collaborative approach to drug development, specifically regarding the immunotherapy TECELRA. After acquiring the treatment in 2025, US WorldMeds prioritized securing full FDA approval while maintaining close ties with advocacy groups. SFA leadership highlighted this strategy as a blueprint for how industry partners can effectively bridge the gap between clinical innovation and patient needs.
In section Releases
US WorldMeds Receives 2026 Vision of Hope Award for Sarcoma Advocacy
At the Stand Up to Sarcoma Gala in New York City, the Sarcoma Foundation of America honored US WorldMeds with its 2026 Vision of Hope Award. The accolade recognizes the company’s efforts to integrate patient perspectives into the development and regulatory pathways for life-saving rare disease therapies.
Breck Jones, Jr., President of US WorldMeds, noted that the company treats the award as a shared victory with the survivors and caregivers who have influenced their scientific trajectory. Brandi Felser, CEO of the Sarcoma Foundation of America, praised the company for its ability to prioritize the patient voice in a field that remains historically underserved and underfunded. This recognition follows a previous 2022 award for the development of TECELRA, which is currently used to treat adults and pediatric patients aged 12 and older with unresectable or metastatic synovial sarcoma.
Comments (0)
No comments yet. Be the first!